Deal focus: Antengene targets unmet cancer problems
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
Despite being the world’s second-largest pharmaceutical market, China isn’t known for its prowess in drug innovation. The country has some of the highest incidence rates for cancer, diabetes and liver...
More on Greater China
Latest News
China 3D printing start-up WeNext raises $55m
Temasek Holdings, Cathay Capital Private Equity, and Haochen Capital have led a $55 million Series B round for WeNext Technology, a China-based 3D printing specialist.
Vision Fund backs Japan sneaker marketplace
SoftBank Vision Fund 2 has made a Series D investment of undisclosed size in Japan’s Soda, operator of sneaker reselling platform Snkr Dunk, at a valuation of JPY38 billion ($336 million).
Chinese language learning platform raises $105m
Singapore’s LingoAce, a Chinese language learning app, has raised $105 million in Series C funding led by Sequoia Capital India. It comes within a year of a $55 million Series B.
CVC backs take-private of Hong Kong-listed Razer
CVC Capital Partners is supporting a proposed founder-led privatization of Hong Kong-listed gaming hardware and software provider Razer that values the business at HK$24.7 billion ($3.17 billion).